KEYNOTE-564 is the first trial to demonstrate an overall survival benefit with adjuvant immunotherapy in patients with clear cell renal cell carcinoma.
Two new studies of the potential neuroprotective agent nerinetide for patients with acute ischemic stroke have shown conflicting results, with suggestions of benefit when given very early in the prehospital setting.
Despite surgical advances, adding extracranial-intracranial bypass to medical therapy does not reduce stroke or death in symptomatic occlusion of the internal carotid or middle cerebral artery.
Liver transplant might cure liver metastases in a small subset of patients with CRC but identifying which patients could benefit most remains a challenge.